This Study is to Describe and Evaluate Patients in Finland Treated With Tofacitinib for the Treatment of Ulcerative Colitis Using Real World Data.

Retrospective Non-interventional Multicenter Patient Chart Data Study on Tofacitinib Realworld Experience in Ulcerative Colitis in Finland (FinTofUC)

The aim of this study is to describe and evaluate clinical outcomes, treatment lines, and to identify the key characteristics of the patients treated with tofacitinib.

Inclusion Criteria:

• Xeljanz (tofacitinib) usage for ulcerative colitis
• Diagnosis of ulcerative colitis (ICD-10: K51.0, K51.1, K51.2, K51.3, K51.5, K51.8, K51.9) between January 2010 and December 2021 (incident or prevalent).

Exclusion Criteria:

• Age < 18 years at the start of tofacitinib use
• Use of tofacitinib before reimbursement (1.3.2019)
• < 8 weeks of treatment with tofacitinib at the start of data mining
• History of panproctocolectomy, IPAA or ileostomy.